Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Arbutus Biopharma Corporation
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
27 mars 2025 07h30 HE
|
Arbutus Biopharma Corporation
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
03 mars 2025 09h15 HE
|
Arbutus Biopharma Corporation
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a...
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
25 févr. 2025 07h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious...
Arbutus Provides 2025 Corporate and Financial Update
13 janv. 2025 07h30 HE
|
Arbutus Biopharma Corporation
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 ...
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
26 nov. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
15 nov. 2024 11h02 HE
|
Arbutus Biopharma Corporation
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15 nov. 2024 11h01 HE
|
Arbutus Biopharma Corporation
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of...
Arbutus to Present at Jefferies London Healthcare Conference
14 nov. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06 nov. 2024 07h30 HE
|
Arbutus Biopharma Corporation
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase...
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
23 oct. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...